N/A N=104 Start Treatment and Recovery for Opioid Use Disorder
Opioid-use Disorder · Mental Disorder · Opioid Medication Assisted Treatment
Primary: Number of Participants With Self-reported Treatment Retention — 51 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=20 Opioid Treatment Program (OTP)-Pharmacy Collaboration for Methadone Maintenance Treatment
Opioid-use Disorder
Primary: Recruitment Rate — 3; 12; 5 Participants
N/A N=105 Mindfulness-Based Relapse Prevention to Improve Medication Assisted Treatment Adherence and Drug-use Outcomes for Opioid Use Disorder
Opioid-use Disorder
Primary: Adherence to Medication Assisted Treatment (MAT) — 32; 17 Participants
N/A N=155 Technology for MAT in Primary Care - Phase 2
Opioid-use Disorder
Primary: Urine Drug Screening Test Results — 92.3; 92.0; 1.9; 2.0 percentage of participants positive
Phase 3 N=653 Prescription Opioid Addiction Treatment Study (POATS)
Opiate Dependence · Substance-related Disorders · Opioid-related Disorders
Primary: The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition at End of Phase 1 — 19; 24 participants
N/A N=160 Computer Based Treatment for Cognitive Behavioral Therapy and Cooperative Pain Education and Self-Management
Opioid Use Disorder · Chronic Pain
Primary: Percent Participants Active in Medications for Opioid Use Disorder (MOUD) Treatment — 91.30; 86.30; 89.90; 83.20 Percent participants — p=0.43
N/A N=119 Improving Reproductive Health for Women in Opioid Medication-Assisted Treatment (OMAT)
Contraception
Primary: Family Planning Visit and Long-acting Reversible Contraception Use at Three and Six Month Follow-up by Condition. — 2; 7; 2; 7 Participants
N/A N=32 CoMBAT Opioid Use Disorder: A Combined Medication and Behavioral Activation Treatment for People Living With Opioid Use Disorder
Opioid-use Disorder · Medication Adherence · Health Care Utilization
Primary: Number of Missed Medication Doses - Past 30 Days — 3.13; 2.81; 3.71; 2.25 Number of missed doses — p=0.17
N/A N=154 Mindfulness Oriented Recovery Enhancement for Chronic Pain and Opioid Relapse
Opioid Use · Chronic Pain
Primary: Drug Relapse Through 16-weeks. — 39; 44 Participants — p=.02
N/A N=30 Pilot of Mindfulness Oriented Recovery Enhancement in MethadoneTreatment
Opioid Use · Chronic Pain
Primary: Study Interest — 32 Participants
Phase 3 N=20 Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial
Opioid-Related Disorders · Heroin Dependence
Primary: The Primary Outcome Will Include a Comparison of the Proportion of Patients Successfully Inducted One Week After the Initial Primary Care Visit. — 6; 6 participants
N/A N=171 Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)
Opioid-use Disorder
Primary: Number of Participants With Retention in Medication Treatment for OUD — 46; 51 Participants — p=0.94
Phase 4 N=19 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Low Back Pain
Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097
Phase 4 N=1,269 Starting Treatment With Agonist Replacement Therapies (START)
Opiate-related Disorders
Primary: Hepatic Safety — 278; 318; 41; 62 participants — p=< 0.05
N/A N=375 Contingency Management to Enhance Office-Based Buprenorphine Treatment
Opioid-use Disorder
Primary: Buprenorphine Adherence as Assessed by the Percentage of Buprenorphine-positive Urine Samples — 80; 84; 78 percentage of urine samples — p==0.22
Phase 4 N=104 Rapid Initiation of Drug Treatment Engagement
Opioid-use Disorder · Overdose
Primary: Enrollment in Medication Assisted Treatment at 1-month Post-enrollment — 33; 1 participants
N/A N=186 Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics)
Opioid-use Disorder
Primary: CM Exposure (Implementation Outcome) — 18; 31 Participants — p=0.097
N/A N=665 Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
Methamphetamine Abuse · Opioid-use Disorder · HIV Seropositivity
Primary: Increase in HIV Viral Suppression for HIV-positive Participants: High- vs. Low-Intensity Frontline Intervention With SMS in Stage 2 — 31; 35; 6; 3 Participants — p=0.447
Phase 2 N=103 Medications Development for Drug Abuse Disorders
Opioid Related Disorders · Opioid Dependence · Opioid Addiction
Primary: Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period. — 7.79; 8.41; 8.28; 6.16…
N/A N=115 Opioid Treatment and Recovery Through a Safe Pain Management Program
Depression · Opioid Use · Chronic Pain
Primary: Odds of Morphine Equivalent Daily Dose (MEDD) of Opioid Prescription >=50 mg — 0.209; 0.417; 0.185; 0.364 odds of prescription high dose — p=0.956
N/A N=131 Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD
Opioid Use Disorder · Pregnancy Related · Substance Use
Primary: Medication for Opioid Use Disorder (MOUD) Knowledge Score — 83.5; 72.0 percentage of correct answers
Phase 3 N=87 Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults
Opioid Dependence
Primary: Change of Opioid Use From Week 1 to 13 — 0.00; 0.27; 0.39 Mean Proportion of Opioid Use in Week 13 — p==0.00874
N/A N=225 A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail
Opioid Use Disorder
Primary: Predicted Probability Derived From the Generalized Linear Mixed Model of Opioid Urine Test Positive Results Over Time — 0.70; 0.72; 0.66; 0.59 Probability — p=.32
Phase 3 N=18 Buprenorphine Group Medical Visits in Primary Care
Opioid-Related Disorders
Primary: Number of Participants With Opioid Abstinence at 8 Weeks — 0; 1 Participants — p=0.44
Phase 2 N=81 Memantine and Naltrexone Treatment for Opioid Dependence
Opioid Dependence
Primary: Retention in Treatment — 7; 5; 6 participants — p=0.32
N/A N=48 SMART Effectiveness Trial
Opioid-use Disorder · Opioid Dependence · Treatment Adherence
Primary: Treatment Adherence — 16; 13 Participants
Phase 2 N=15 Testosterone Replacement for Male Opioid Agonist Maintained Patients
Chronic Pain · Opioid Addiction · Symptomatic Hypogonadism
Primary: Number of Participants Demonstrating Abstinence — 5; 4 Participants
N/A N=80 A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses
Drug Overdose · Opioid-Related Disorders · Drug Addiction
Primary: Medication-Assisted Treatment Enrollment — 7; 13 Participants
N/A N=100 Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients
Tobacco Use Disorder · Medication Adherence
Primary: Varenicline Adherence as Measured by Pill Count — 61.8; 78.5 percentage pills taken/pills dispensed
N/A N=102 Optimizing Pregnancy and Treatment Interventions for Moms 2.0
Pregnancy, High Risk · Opioid-Related Disorders · Pregnancy Related
Primary: Opioid Use Disorder (OUD) and Other Substance Use Disorder (SUD) Treatment Linkage/Retention — -1.5; -8.8 Percentage of days